Austrian Breast & Colorectal Cancer Study Group

Science from the heart of Europe

Enrollment completed ahead of schedule for the ABCSG 63 / ERIKA trial

13.07.2026

Recruitment for the phase II ABCSG 63 / ERIKA trial has been successfully completed. With the randomization of the 120th patient, the study reached its enrollment target two months ahead of schedule.

Latest Big-Newsletter reports on the ABCSG 63 / ERIKA Trial

17.04.2024

ABCSG 63 / ERIKA (Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer) trial to start study recruitment in Q2 2024!

ABCSG 63 is an innovative, investigator-initiated trial in its final set-up phase, to be conducted in Austria and Germany under the academic sponsorship of ABCSG, and at approximately 18 trial sites with the recruitment target of 120 patients.